Pages that link to "Q51918651"
Jump to navigation
Jump to search
The following pages link to Standardization of HER2 testing: results of an international proficiency-testing ring study (Q51918651):
Displaying 50 items.
- Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection (Q26801745) (← links)
- HER2 testing in gastric cancer: a practical approach (Q28256814) (← links)
- Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011). (Q30813968) (← links)
- Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid (Q33378811) (← links)
- Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. (Q33529063) (← links)
- Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity (Q33643786) (← links)
- Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study (Q33688726) (← links)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update (Q33862786) (← links)
- Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation (Q34044859) (← links)
- TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma (Q34044864) (← links)
- Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification (Q34084063) (← links)
- Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark®) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens (Q34342079) (← links)
- Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas (Q34852929) (← links)
- SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases (Q34855870) (← links)
- Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study (Q35078787) (← links)
- Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival (Q35343184) (← links)
- Internal Quality Assurance Program for ERBB2 (HER2) Testing Improves the Selection of Breast Cancer Patients for Treatment with Trastuzumab. (Q35788769) (← links)
- Reduced risk of breast cancer associated with recreational physical activity varies by HER2 status (Q35928943) (← links)
- 68Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET (Q36085489) (← links)
- Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach (Q36245435) (← links)
- Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study (Q36458767) (← links)
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). (Q36649356) (← links)
- HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer (Q36903047) (← links)
- Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists (Q36944264) (← links)
- Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations (Q37127007) (← links)
- External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale (Q37153505) (← links)
- EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy (Q37206247) (← links)
- Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial (Q37240710) (← links)
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. (Q37273361) (← links)
- Epidermal growth factor receptor protein expression and gene amplification in normal, hyperplastic, and cancerous glottic tissue: immunohistochemical and fluorescent in situ hybridization study on tissue microarrays (Q37309072) (← links)
- Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer (Q37335142) (← links)
- Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules (Q37453801) (← links)
- Antibody validation (Q37479212) (← links)
- A Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis (Q37737860) (← links)
- Molecular assays in breast cancer pathology (Q37828343) (← links)
- Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel (Q37862646) (← links)
- Re-overcoming barriers in translating biomarkers to clinical practice (Q38088713) (← links)
- Evaluation of HER2 in breast cancer: reality and expectations. (Q38089837) (← links)
- Pragmatic issues in biomarker evaluation for targeted therapies in cancer (Q38271031) (← links)
- HER2 assessment by silver in situ hybridization: where are we now? (Q38314355) (← links)
- Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens (Q38612634) (← links)
- Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections (Q38758647) (← links)
- Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance (Q39238692) (← links)
- An optimized image analysis algorithm for detecting nuclear signals in digital whole slides for histopathology. (Q40466552) (← links)
- Measurement of HER2 in saliva of women in risk of breast cancer. (Q44386208) (← links)
- 'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases (Q44639508) (← links)
- False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma. (Q47981933) (← links)
- Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough? (Q48155048) (← links)
- Interpretation of HER2 tests in gastric cancer: confirmation of interobserver differences and validation of a QA/QC educational program (Q48523290) (← links)
- Standardization and optimization of fluorescence in situ hybridization (FISH) for HER-2 assessment in breast cancer: A single center experience (Q49494949) (← links)